In a concerning development that echoes the recent COVID-19 “vaccine” saga, pharmaceutical giant Moderna has secured a whopping $176 million from the U.S. government to fast-track the development of a new mRNA flu vaccine. This vaccine is purportedly designed to protect against both seasonal influenza and bird flu viruses currently circulating in the United States. As Moderna prepares to kick off clinical trials next year, working closely with the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), questions arise about the true motives and implications of this massive investment.